Drug Approval | June 27, 2025
SMS Pharmaceuticals completes USFDA inspection at Central Laboratory Analytical Services
The inspection concluded with zero Form 483 observations
The inspection concluded with zero Form 483 observations
This significant milestone enhances our global regulatory standing
The inspection, conducted from March 17 to March 21, 2025, concluded with one observation in Form 483
The inspection conducted by EDQM at its Visakhapatnam facility
SMS Pharmaceuticals has reported total income of Rs. 165.81 crores during the quarter ended June 30, 2024
EDQM conducts GMP inspection of SMS Pharmaceuticals’ API facility
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Within the API segment, ~20% of the revenues came from the domestic market and ~80% from the exports market
The company has reported total income of Rs. 65.19 crores during the period ended June 30, 2022.
With this, the company can start selling Ibuprofen in the European markets.
Subscribe To Our Newsletter & Stay Updated
